Everything you care about in one place
Follow feeds: blogs, news, RSS and more. An effortless way to read and digest content of your choice.
Get Feedergsk.com
Press releases
Get the latest updates from Press releases directly as they happen.
Follow now 544 followers
Latest posts
Last updated 18 days ago
Gepotidacin accepted for priority review by the US FDA for the oral treatment of uncomplicated urogenital gonorrhoea
18 days ago
Submission supported by positive phase III data in patients with uncomplicated urogenital...
GSK provides update on US settlement of CureVac/BioNTech mRNA patent litigation
21 days ago
CureVac will make an upfront settlement of $370 million to GSK
GSK highlights new findings on Dementia and Alzheimer’s Disease at AAIC 2025, building on leadership in immunology and inflammation
about 1 month ago
Real-world data shows an association between Recombinant Zoster Vaccine (RZV) and potential...
GSK and Hengrui Pharma enter agreements to develop up to 12 innovative medicines across Respiratory, Immunology & Inflammation and Oncology
about 1 month ago
Includes license for potential best-in-class PDE3/4 inhibitor (HRS-9821) in clinical development for...
Blenrep (belantamab mafodotin) combinations approved in EU for treatment of relapsed/refractory multiple myeloma
about 1 month ago
Sixth regulatory approval for Blenrep combinations with applications under review in all...
GSK announces extension of US Food and Drug Administration review period for Blenrep (belantamab mafodotin-blmf) in relapsed/refractory multiple myeloma
about 1 month ago
New PDUFA date scheduled for 23 October 2025.
GSK provides update on US FDA advisory committee review of Blenrep (belantamab mafodotin-blmf) combinations for patients with relapsed/refractory multiple myeloma
about 1 month ago
The US FDA Oncologic Drugs Advisory Committee voted against the proposed dosage...
US FDA approves GSK’s Shingrix in a prefilled syringe presentation
about 1 month ago
Prefilled syringe presentation offers a convenient administration option to healthcare professionals
ViiV Healthcare extends voluntary licensing agreement with Medicines Patent Pool to enable access to innovative long-acting injectable HIV treatment
about 2 months ago
Agreement allows manufacturers to develop, manufacture and supply generic LA injectable cabotegravir...
ViiV Healthcare data show 89% of treatment-naïve people with HIV choose to switch to long-acting injectable Vocabria + Rekambys from daily pills after achieving rapid viral suppression
about 2 months ago
Multiple real-world studies show consistent high effectiveness of Vocabria + Rekambys across...
US FDA accepts application to review expanded use of GSK’s RSV vaccine, Arexvy, for adults 18-49 at increased risk
about 2 months ago
More than 21 million US adults under the age of 50 have...